Charles Gross

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent

Bed Bath & Beyond Option Alert: Mar 3 $3 Calls Sweep (6) near the ... - Benzinga

Market On Close Imbalance: $1B To BUY-Side - SPDR S&P 500 ... - Benzinga

NFIB Small Business Optimism for Jan 90.3 Vs Consensus 90.9 ... - Benzinga

https://www.ft.com/content/b41bdc29-3a1f-4ff6-9872-f0625c505b46

On February 24, 2023, Sunshine Biopharma, Inc. (the "Company") entered into an Exclusive Patent License Agreement (the "License Agreement") with Arizona Board ofRegents on behalf of the University of Arizona (the "University").

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced the U.S.

-Reuters

-Reuters

Positive high-level results from an analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) met the prespecified target for objective response rate (ORR) and demonstrated durable response across multiple HER2-expressing advanced solid tumours in heavily pretreated patients.